BIORA THERAPEUTICS, INC.: Nasdaq/NYSE listing notice — Biora receives Nasdaq delisting notice for minimum bid price non-compliance

BIORA THERAPEUTICS, INC.

Nasdaq Staff notified Biora on Dec 6, 2022 that it fails to meet the minimum bid price requirement under Listing Rule 5450(a)(1).
Company will request a hearing before the Nasdaq Hearings Panel, which will stay any further delisting action pending a decision.
Biora filed a proxy statement on Nov 29 for a Dec 19 special meeting to authorize a reverse stock split (ratio 5:1 to 25:1) as part of a compliance plan.
There is no immediate impact on trading of common stock (symbol BIOR) while the hearing process is ongoing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIORA THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 6, 2022, Biora Therapeutics, Inc. (the “ Company ”) received a determination from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, due to the Company’s continued non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “ Rule ”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”). The Company plans to timely request a hearing before the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-301868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.